These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8695265)

  • 41. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen and prostate gland volume: correlation and clinical application.
    Babaian RJ; Fritsche HA; Evans RB
    J Clin Lab Anal; 1990; 4(2):135-7. PubMed ID: 1690280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking.
    Kittl EM; Ruckser R; Rech-Weichselbraun I; Hinterberger W; Bauer K
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):81-4. PubMed ID: 9056747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantification of prostatic cancer metastatic disease using prostate-specific antigen.
    Vesey SG; Goble M; Ferro MA; Stower MJ; Hammonds JC; Smith PJ
    Urology; 1990 Jun; 35(6):483-6. PubMed ID: 1693796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL; Deng FM; Feng T
    Zhonghua Yi Xue Za Zhi; 1994 May; 74(5):306-8, 327. PubMed ID: 7525028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.
    Carter HB; Morrell CH; Pearson JD; Brant LJ; Plato CC; Metter EJ; Chan DW; Fozard JL; Walsh PC
    Cancer Res; 1992 Jun; 52(12):3323-8. PubMed ID: 1375867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
    Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Serum Assay of Soluble CD44 Standard, CD44 Variant 5, and CD44 Variant 6 in Patients with Gastric Cancer.
    Yoo CH; Noh SH
    Cancer Res Treat; 2003 Feb; 35(1):3-8. PubMed ID: 26680908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
    Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
    J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.